605 related articles for article (PubMed ID: 26917546)
21. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning?
Liu X; Khalvati F; Namdar K; Fischer S; Lewis S; Taouli B; Haider MA; Jhaveri KS
Eur Radiol; 2021 Jan; 31(1):244-255. PubMed ID: 32749585
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Value of Serum Biomarkers in Combined Hepatocelluar-Cholangiocarcinoma.
Chen J; Li Y; Yu G
J Coll Physicians Surg Pak; 2020 Mar; 30(3):263-267. PubMed ID: 32169133
[TBL] [Abstract][Full Text] [Related]
23. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK
Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861
[TBL] [Abstract][Full Text] [Related]
25. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
[TBL] [Abstract][Full Text] [Related]
26. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.
Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG
Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599
[TBL] [Abstract][Full Text] [Related]
27. Management of combined hepatocellular and cholangiocarcinoma.
Kassahun WT; Hauss J
Int J Clin Pract; 2008 Aug; 62(8):1271-8. PubMed ID: 18284443
[TBL] [Abstract][Full Text] [Related]
28. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
29. Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma.
Sagrini E; Iavarone M; Stefanini F; Tovoli F; Vavassori S; Maggioni M; Renzulli M; Salvatore V; Stefanescu H; Colombo M; Bolondi L; Piscaglia F
United European Gastroenterol J; 2019 Feb; 7(1):69-77. PubMed ID: 30788118
[TBL] [Abstract][Full Text] [Related]
30. Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma.
Shetty AS; Fowler KJ; Brunt EM; Agarwal S; Narra VR; Menias CO
Abdom Imaging; 2014 Apr; 39(2):310-22. PubMed ID: 24407728
[TBL] [Abstract][Full Text] [Related]
31. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Yoon YI; Hwang S; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Lee JW; Hong SM; Yu ES; Lee SG
J Gastrointest Surg; 2016 Feb; 20(2):411-20. PubMed ID: 26628072
[TBL] [Abstract][Full Text] [Related]
32. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound.
Galassi M; Iavarone M; Rossi S; Bota S; Vavassori S; Rosa L; Leoni S; Venerandi L; Marinelli S; Sangiovanni A; Veronese L; Fraquelli M; Granito A; Golfieri R; Colombo M; Bolondi L; Piscaglia F
Liver Int; 2013 May; 33(5):771-9. PubMed ID: 23445369
[TBL] [Abstract][Full Text] [Related]
33. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.
Zhou C; Wang Y; Ma L; Qian X; Yang C; Zeng M
Eur Radiol; 2022 Jan; 32(1):78-88. PubMed ID: 34279688
[TBL] [Abstract][Full Text] [Related]
34. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.
Na SK; Choi GH; Lee HC; Shin YM; An J; Lee D; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
PLoS One; 2018; 13(6):e0198138. PubMed ID: 29879137
[TBL] [Abstract][Full Text] [Related]
35. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
37. Combined hepatocellular carcinoma and cholangiocarcinoma: a case report and review of the literature.
Zhou YM; Yang JM; Wang B; Xu F; Tong Y; Li DQ
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):656-9. PubMed ID: 18086637
[TBL] [Abstract][Full Text] [Related]
38. Imaging features of combined hepatocellular-cholangiocarcinoma on contrast-enhanced ultrasound: correlation with clinicopathological findings.
Ye J; Xie X; Lin Y; Liu B; Wang W; Huang X; Huang G
Clin Radiol; 2018 Mar; 73(3):237-243. PubMed ID: 29122222
[TBL] [Abstract][Full Text] [Related]
39. Comparison contrast-enhanced CT with contrast-enhanced US in diagnosing combined hepatocellular-cholangiocarcinoma: a propensity score-matched study.
Yang J; Zhang Y; Bao WY; Chen YD; Jiang H; Huang JY; Zeng KY; Song B; Huang ZX; Lu Q
Insights Imaging; 2024 Feb; 15(1):44. PubMed ID: 38353807
[TBL] [Abstract][Full Text] [Related]
40. Combined hepatocellular-cholangiocarcinoma. Diagnostic challenge in hepatic fine needle aspiration biopsy.
Wee A; Nilsson B
Acta Cytol; 1999; 43(2):131-8. PubMed ID: 10097699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
